Nieves Purificacion
Martinez Lago
![Foto de Nieves Purificacion](/img/nophoto.png)
![Foto de Complexo Hospitalario Universitario de Ourense](/img/noimage_org.png)
Complexo Hospitalario Universitario de Ourense
Orense, EspañaPublicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Ourense (12)
2024
-
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON–SEOM registry
Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1674-1686
2023
-
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 4077-4089
-
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy
Therapeutic Advances in Medical Oncology, Vol. 15
2022
-
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen
PLoS ONE, Vol. 17, Núm. 6 June
-
Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
ESMO Open, Vol. 7, Núm. 3
2021
-
Do clinical trials meet current care needs? Views of digestive oncology specialists in galicia (spain) using the delphi method
Healthcare (Switzerland), Vol. 9, Núm. 6
-
Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
BMC Cancer, Vol. 21, Núm. 1
-
External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry
Therapeutic Advances in Medical Oncology, Vol. 13
-
Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry
Gastric Cancer, Vol. 24, Núm. 4, pp. 926-936
-
Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data
Scientific Reports, Vol. 11, Núm. 1
2019
-
Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen
Annals of Oncology, Vol. 30, pp. iv42-iv43
-
Is there any affordable and reliable score in local gastric cancer?
Annals of Oncology, Vol. 30, pp. iv60